Skip to content

Study · Randomized controlled trial · n = 18 · 2019

9 results

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial.

Naimi RM, Hvistendahl M, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Grønbæk H, Møller HJ, Vilstrup H, Steensberg A, Jeppesen PB

EBioMedicine17 Jul 2019Cited by 25 (Europe PMC)

PMID31326433 (opens in a new tab)PMCIDPMC6710908 (opens in a new tab)DOI10.1016/j.ebiom.2019.07.016 (opens in a new tab)PepBankPUB-31326433
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, transient elastography values increased from baseline during glepaglutide treatment.

    In plain wordsIn patients with short bowel syndrome, transient elastography values increased from baseline during glepaglutide treatment.

    Peptide
    Glepaglutide
    Outcome
    IncreaseTransient elastography
    Study

    n = 18

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · three weeksAs given in this study (human).

    Source sentences

    Summary
    Treatment with glepaglutide was associated with increase in TE and ICG-elimination.
    1 context sentence
    Summary · context
    Liver tests, transient elastography (TE) with controlled attenuation parameter (CAP), indocyanine green (ICG) kinetics, soluble CD163 (sCD163), soluble mannose receptor (sMR), and lipopolysaccharide binding protein (LBP) were assessed in 18 patients with SBS in a randomised, cross-over, dose-finding…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, indocyanine green elimination increased from baseline during glepaglutide treatment.

    In plain wordsIn patients with short bowel syndrome, indocyanine green elimination increased from baseline during glepaglutide treatment.

    Peptide
    Glepaglutide
    Outcome
    IncreaseIndocyanine green elimination
    Study

    n = 18

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · three weeksAs given in this study (human).

    Source sentences

    Summary
    Treatment with glepaglutide was associated with increase in TE and ICG-elimination.
    1 context sentence
    Summary · context
    Liver tests, transient elastography (TE) with controlled attenuation parameter (CAP), indocyanine green (ICG) kinetics, soluble CD163 (sCD163), soluble mannose receptor (sMR), and lipopolysaccharide binding protein (LBP) were assessed in 18 patients with SBS in a randomised, cross-over, dose-finding…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide did not affect controlled attenuation parameter relative to baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide did not affect controlled attenuation parameter relative to baseline.

    Peptide
    Glepaglutide
    Outcome
    No significant changeControlled attenuation parameter
    Study

    n = 18

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · three weeksAs given in this study (human).

    Source sentences

    Summary
    CAP, sMR, LBP, liver transaminases, and INR were not affected.
    1 context sentence
    Summary · context
    Liver tests, transient elastography (TE) with controlled attenuation parameter (CAP), indocyanine green (ICG) kinetics, soluble CD163 (sCD163), soluble mannose receptor (sMR), and lipopolysaccharide binding protein (LBP) were assessed in 18 patients with SBS in a randomised, cross-over, dose-finding…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide did not affect soluble mannose receptor relative to baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide did not affect soluble mannose receptor relative to baseline.

    Peptide
    Glepaglutide
    Outcome
    No significant changeSoluble mannose receptor
    Study

    n = 18

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · three weeksAs given in this study (human).

    Source sentences

    Summary
    CAP, sMR, LBP, liver transaminases, and INR were not affected.
    1 context sentence
    Summary · context
    Liver tests, transient elastography (TE) with controlled attenuation parameter (CAP), indocyanine green (ICG) kinetics, soluble CD163 (sCD163), soluble mannose receptor (sMR), and lipopolysaccharide binding protein (LBP) were assessed in 18 patients with SBS in a randomised, cross-over, dose-finding…
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide did not affect lipopolysaccharide binding protein relative to baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide did not affect lipopolysaccharide binding protein relative to baseline.

    Peptide
    Glepaglutide
    Outcome
    No significant changeLipopolysaccharide binding protein
    Study

    n = 18

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · three weeksAs given in this study (human).

    Source sentences

    Summary
    CAP, sMR, LBP, liver transaminases, and INR were not affected.
    1 context sentence
    Summary · context
    Liver tests, transient elastography (TE) with controlled attenuation parameter (CAP), indocyanine green (ICG) kinetics, soluble CD163 (sCD163), soluble mannose receptor (sMR), and lipopolysaccharide binding protein (LBP) were assessed in 18 patients with SBS in a randomised, cross-over, dose-finding…
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide did not affect liver transaminases relative to baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide did not affect liver transaminases relative to baseline.

    Peptide
    Glepaglutide
    Outcome
    No significant changeLiver transaminases
    Study

    n = 18

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · three weeksAs given in this study (human).

    Source sentences

    Summary
    CAP, sMR, LBP, liver transaminases, and INR were not affected.
    1 context sentence
    Summary · context
    Liver tests, transient elastography (TE) with controlled attenuation parameter (CAP), indocyanine green (ICG) kinetics, soluble CD163 (sCD163), soluble mannose receptor (sMR), and lipopolysaccharide binding protein (LBP) were assessed in 18 patients with SBS in a randomised, cross-over, dose-finding…
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide did not affect INR relative to baseline.

    In plain wordsIn patients with short bowel syndrome, glepaglutide did not affect INR relative to baseline.

    Peptide
    Glepaglutide
    Outcome
    No significant changeINR
    Study

    n = 18

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · three weeksAs given in this study (human).

    Source sentences

    Summary
    CAP, sMR, LBP, liver transaminases, and INR were not affected.
    1 context sentence
    Summary · context
    Liver tests, transient elastography (TE) with controlled attenuation parameter (CAP), indocyanine green (ICG) kinetics, soluble CD163 (sCD163), soluble mannose receptor (sMR), and lipopolysaccharide binding protein (LBP) were assessed in 18 patients with SBS in a randomised, cross-over, dose-finding…
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide 10 mg increased soluble CD163 by 0·44 mg/mL from baseline (P = 0·0498).

    In plain wordsIn patients with short bowel syndrome, the 10 mg dose of glepaglutide increased soluble CD163 from baseline.

    Peptide
    Glepaglutide
    Outcome
    IncreaseSoluble CD163
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    10 mg · three weeksAs given in this study (human).

    Measurements

    Change in sCD163
    0.44 mg/mL
    10 mg dose group, change from baseline

    Source sentences

    Summary
    In the 10 mg dose group, glepaglutide increased sCD163 by 0·44 mg/mL (P = 0·0498), and alkaline phosphatase (ALP) decreased in the 1 mg dose group by 33 U/L (P = 0·032).
    1 context sentence
    Summary · context
    Liver tests, transient elastography (TE) with controlled attenuation parameter (CAP), indocyanine green (ICG) kinetics, soluble CD163 (sCD163), soluble mannose receptor (sMR), and lipopolysaccharide binding protein (LBP) were assessed in 18 patients with SBS in a randomised, cross-over, dose-finding…
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with short bowel syndrome, glepaglutide 1 mg decreased alkaline phosphatase by 33 U/L from baseline (P = 0·032).

    In plain wordsIn patients with short bowel syndrome, the 1 mg dose of glepaglutide decreased alkaline phosphatase from baseline.

    Peptide
    Glepaglutide
    Outcome
    DecreaseAlkaline phosphatase
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1 mg · three weeksAs given in this study (human).

    Measurements

    Decrease in alkaline phosphatase
    33 U/L
    1 mg dose group, change from baseline

    Source sentences

    Summary
    In the 10 mg dose group, glepaglutide increased sCD163 by 0·44 mg/mL (P = 0·0498), and alkaline phosphatase (ALP) decreased in the 1 mg dose group by 33 U/L (P = 0·032).
    1 context sentence
    Summary · context
    Liver tests, transient elastography (TE) with controlled attenuation parameter (CAP), indocyanine green (ICG) kinetics, soluble CD163 (sCD163), soluble mannose receptor (sMR), and lipopolysaccharide binding protein (LBP) were assessed in 18 patients with SBS in a randomised, cross-over, dose-finding…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT02690025

A Phase 2 Trial Testing ZP1848 in Patients With SBS

Zealand Pharman = 18Feb 2016 to May 2017

Short Bowel Syndrome

Trial pageClinicalTrials.govUpdated 21 Jun 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.